Ditch the razor and get 21% off the Braun smart IPL with 4K already sold
Summer's not over yet, and now that your legs have a little glow, it's the perfect time to get smoother skin while you're rocking those short shorts.
If you're tired of the constant cycle of shaving, waxing, or booking expensive salon laser appointments, the Braun Silk-Expert Pro 5 might be the home solution you've been looking for.
Reduce cuts on your legs from hastily shaving before work. Think no more cuts, just smooth-looking legs. This FDA-cleared IPL (intense pulsed light) device promises up to 97% hair reduction in just four to twelve weeks when used consistently.
Advertisement
It uses smart SensoAdapt technology to automatically adjust the intensity based on your skin tone for a safe, effective treatment every time. With up to 400,000 flashes, it's designed to last for years, and treat your full body in minutes thanks to its high-speed flash rate.
If you're searching for the best fit, check out our review of the top IPL hair removal devices on the market. Ready for immaculate, hair-free legs? Join the beauty club at a discount with Braun.
Amazon
It's pain-free, without yanking or waxing strips. Just a quick, gentle flash of light with a precision head for trickier areas like your face, underarms, and bikini line, so you can go full spa-mode at home. That's right, you don't have to worry about those awkward, one-leg-up poses at the salon.
For over 200 years, the New York Post has been America's go-to source for bold news, engaging stories, in-depth reporting, and now, insightful shopping guidance. We're not just thorough reporters – we sift through mountains of information, test and compare products, and consult experts on any topics we aren't already schooled specialists in to deliver useful, realistic product recommendations based on our extensive and hands-on analysis. Here at The Post, we're known for being brutally honest – we clearly label partnership content, and whether we receive anything from affiliate links, so you always know where we stand. We routinely update content to reflect current research and expert advice, provide context (and wit) and ensure our links work. Please note that deals can expire, and all prices are subject to change.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
40 minutes ago
- Business Wire
Porosome Therapeutics Announces Breakthrough Alzheimer's Discoveries
BOSTON--(BUSINESS WIRE)-- Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced key advancements in its first-in-class, disease-modifying neurological platform, which will transform Alzheimer's Disease (AD) research and treatment by offering a new approach that goes beyond symptom management. Following the recent FDA validation of organoid-based studies, the company has demonstrated a relatively rapid reduction of the Alzheimer's pathology in AD human brain organoids treated with its principal therapy; shown a significant reduction of the Tau protein, acknowledged by the Food and Drug Administration (FDA) as an AD biomarker, in other studies; and established new classes of AD therapeutics. Implementing the company's signature ' Reprogram, Restore, and Rescue ' strategy, researchers introduce healthy porosomes – neuronal secretory nanomachines – into diseased neurons to target the root causes of AD. By restoring the neuron's secretory and metabolic systems, Porosome Therapeutics' first-of-its-kind approach addresses the cellular function of AD rather than traditional symptom management. 'Unlike therapies that merely dissolve beta amyloid plaques, our platform directly targets the core biological dysfunctions of Alzheimer's, restoring both neurotransmission and metabolic integrity,' said Guillermo Marmol, CEO, Porosome Therapeutics. 'Given Alzheimer's is a serious and life-threatening disease with no effective treatment options, and based on our ability to deliver quantifiable, biomarker-driven improvements, including Tau reduction and disease reversal in human brain organoids, we are actively exploring the FDA's accelerated approval pathway.' In recent studies, the company's approach to porosome restoration has been shown to significantly reduce Tau protein levels – a key FDA-approved biomarker of Alzheimer's. The FDA's recent approval of the Tau test is a landmark development in the research for AD therapies, catalyzed by the groundbreaking science of Porosome Therapeutics. Furthermore, the company's therapeutic approach has been validated using FDA-recommended human brain organoid models, demonstrating fast clinical results with a significant reversal of Alzheimer's pathology shown within two weeks. Organoid models are three-dimensional cell cultures derived from stem cells that mimic the structure and function of human organs. 'When using human brain organoids, we're able to observe the molecular activity of the porosome at an entirely new scale,' said Bhanu P. Jena, PhD, Founder and Chairman, Porosome Therapeutics, and a distinguished cell biologist known for his discovery of the porosome nanomachine, the secretory portal of the cell. 'The ability to create an immense impact in just two weeks is a promising step forward and marks an important milestone as we advance the future of Alzheimer's research and care.' In a complementary development, the company is leveraging artificial intelligence (AI) to design proprietary decoy peptides that target and neutralize the toxic beta amyloid peptide (1-42), which is known for disrupting protein-protein interactions within the neuronal porosome complex and impairing neurotransmitter release. These specially designed AI-decoys bind more strongly to the beta amyloid (1-42), diverting the peptide from interfering with essential porosome functions. With these advances, Porosome Therapeutics has identified three distinct therapeutic classes for AD: Small Molecules and Peptides – Cross the blood-brain barrier to restore mitochondrial function. Biologics – Reconstitute the porosome complex to reverse neuronal secretory dysfunction. AI-Designed Peptides – Decoy peptides designed by AI to neutralize beta amyloid peptides (1-42) and protect neurotransmission. Porosome Therapeutics has expanded its portfolio of products to reflect these breakthroughs and the company's commitment to advancing novel treatment modalities beyond the current standard of care. About Porosome Therapeutics, Inc. Porosome Therapeutics, Inc. is a biopharmaceutical company based in Boston that leverages the groundbreaking discovery of the porosome — the cell's essential secretory machinery. The company employs innovative technologies to identify and develop proprietary therapeutics aimed at currently undruggable porosome proteins linked to secretory and hydration disorders such as cystic fibrosis, diabetes, and cancer. Porosome Therapeutics is the first company to employ a technology platform dedicated to creating novel therapies targeting the porosome, recognized as the universal secretory machinery in cells. This platform is built on decades of research and is supported by over 200 published studies, proving effective against various serious diseases involving secretory defects. The platform focuses on highly specific nanobody-mediated therapies, aiming to significantly reduce drug side effects. Porosome Therapeutics' work on Alzheimer's Disease is carried out through a subsidiary, NeuroTher LLC.
Business Insider
41 minutes ago
- Business Insider
Save 40% on a dentist-approved water flosser with this Waterpik Aquarius deal
Brushing and flossing our teeth regularly is the best thing we can do to maintain our dental health. But what you might not know is that a good water flosser can be even more effective than regular floss at eliminating hard-to-reach plaque and buildup. Water flossers do tend to come at a much higher price point than manual floss, though. Luckily, you can get one of our favorites, the Waterpik Aquarius Water Flosser, on sale right now for one of the lowest prices we've ever seen at Amazon. This water flosser removes up to 99.9% of plaque from treated areas and is up to 50% more effective than floss. It also has a massage mode for gum stimulation and 10 pressure settings. Waterpik is the first water flosser brand to receive the American Dental Association (ADA) Seal of Acceptance and has been the number one dentist-recommended brand for years. Our editors on the Reviews Team also tested out Waterpik's Electric Toothbrush & Water Flosser Combo for themselves and were impressed with the noticeable results it delivered. Check out our full review to learn Aquarius Water Flosser packs everything we love about other Waterpiks we've tried. It has 10 pressure settings to clean your teeth effectively. Seven tips are included, all of which can rotate 360 degrees to clean hard-to-reach spots. The 22-ounce water reservoir is removable and dishwasher safe for easy cleaning and holds enough water to run the flosser for 90 seconds uninterrupted. Plus, the flosser has a built-in timer that pulses to allow you to keep track of your flossing nearly 115,000 five-star ratings on Amazon, it's clear that shoppers love this water flosser as much as we do. "The Waterpik Aquarius Water Flosser has completely elevated my oral hygiene routine. It's easy to use, powerful, and leaves my mouth feeling cleaner than regular floss ever has. The 10 pressure settings are great—I started low and gradually increased to find the level that's best for me," said one reviewer. "I love that it has a built-in timer to guide you through a full cleaning cycle, and the water reservoir is large enough that I don't need to refill it mid-use."Many shoppers said they'd never go back to just manual flossing after buying a Waterpik. "Simply put, this is the best investment in dental hygiene I've ever made. I'll never be without one again," said another reviewer. "The larger water reservoir means I can take my time. The way the basic tips are bent makes it very easy to direct the water carefully."With the current discount on Amazon, you can get the Waterpik Aquarius Water Flosser for 40% off the original price. Add it to your cart now for just $60 while the deal shopping? Browse through more of Amazon's health and household deals.
Epoch Times
41 minutes ago
- Epoch Times
FDA Issues Update on Most Serious Recall for Certain Ventilators
The Food and Drug Administration (FDA) issued a notice warning that medical ventilators made by Philips Respironics are still under a Class I recall due to the potential for serious injury or death. The agency noted that the recall notice for the company's V30, A30, and A40 ventilators, which are used for obstructive sleep apnea (OSA), primarily 'involves correcting devices and does not involve removing them from where they are used or sold.'
